Pegfilgrastim Given Same Day as or Day After Carboplatin and Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Lung Cancer, Non-Small Cell Lung Cancer
Both
Lung Cancer, Non-Small Cell Lung Cancer
Trial Information
Pegfilgrastim Given Same Day as or Day After Carboplatin and Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Inclusion Criteria
Eligibility Criteria: - Age 18 years or older - Diagnosis of advanced or metastatic
non-small cell lung cancer (NSCLC) - Have not received any prior chemotherapy - Have not
received radiation therapy or undergone major surgery within the past 2 weeks
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
incidence of infection
Outcome Time Frame:
during treatment
Safety Issue:
No
Principal Investigator
MD
Investigator Role:
Study Director
Investigator Affiliation:
Amgen
Authority:
United States: Food and Drug Administration
Study ID:
20030123
NCT ID:
NCT00094822
Start Date:
July 2003
Completion Date:
February 2006
Related Keywords:
- Lung Cancer
- Non-Small Cell Lung Cancer
- Metastatic Cancer
- Neulasta®
- pegfilgrastim
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
